Chimeric Therapeutics Ltd (ASX: CHM) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Chimeric Therapeutics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $15.53 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 862.72 million
Earnings per share -0.027
Dividend per share N/A
Year To Date Return -51.43%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Chimeric Therapeutics Ltd (ASX: CHM)
    Latest News

    A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
    Healthcare Shares

    Guess which ASX micro-cap stock is rocketing 80% on FDA clearance

    The FDA has given the thumbs up to this company's trial plans.

    Read more »

    a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
    Healthcare Shares

    Do ASX biotech shares offer 'good buying' after the sell-off? Experts weigh in

    After some strong support in early 2021, biotechnology stocks took a beating over the past 6 months.

    Read more »

    Happy child jumping for joy.
    Share Gainers

    The Chimeric (ASX:CHM) share price jumps 6% on patent success

    Chimeric's shares are on the move this afternoon. Here's the details.

    Read more »

    Two staff in a medical research laboratory wearing masks and caps work on their tests, representing the performance of ASX healthcare shares in FY22
    Healthcare Shares

    The Chimeric (ASX:CHM) share price drops despite cancer trial news

    An update on its cancer therapy trials fails to spur the Chimeric Therapeutics (ASX: CHM) share price today

    Read more »

    woman in lab coat conducting testing representing biotech
    Share Market News

    Chimeric (ASX:CHM) share price finishes flat on quarterly update

    The Chimeric Therapeutics Ltd (ASX: CHM) share price seesawed today following the release of its quarterly update. Here's the key…

    Read more »

    asx share price fall represented by lady in striped tshirt making sad face against orange background
    Share Market News

    Chimeric (ASX:CHM) share price edges lower despite positive update

    The Chimeric Therapeutics Ltd (ASX: CHM) share price is sliding in afternoon trade despite a positive update. Here's what the…

    Read more »

    falling asx share price represented by woman making sad face
    Share Market News

    Chimeric (ASX:CHM) share price falls despite positive update

    The Chimeric (ASX: CHM) share price is down 6% today despite the company announcing progress on its phase 1 CLTX…

    Read more »

    pile of coins and the letters IPO with a red arrow going up, indicating newly listed shares price gains
    Share Market News

    Chimeric Therapeutics (ASX:CHM) share price jumps 88% following its IPO

    The Chimeric Therapeutics (ASX:CHM) share price rocketed 88% at one stage on Monday following the completion of its IPO...

    Read more »

    CHM ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Chimeric Therapeutics Ltd

    Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

    CHM Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    17 Jun 2024 $0.02 $0.00 0.00% 2,646,076 $0.02 $0.02 $0.02
    14 Jun 2024 $0.02 $0.00 0.00% 1,017,000 $0.02 $0.02 $0.02
    13 Jun 2024 $0.02 $0.00 0.00% 3,037,579 $0.02 $0.02 $0.02
    12 Jun 2024 $0.02 $0.00 0.00% 2,015,091 $0.02 $0.02 $0.02
    11 Jun 2024 $0.02 $0.00 0.00% 2,808,521 $0.02 $0.02 $0.02
    07 Jun 2024 $0.02 $0.00 0.00% 1,459,086 $0.02 $0.02 $0.02
    06 Jun 2024 $0.02 $0.00 0.00% 4,006,591 $0.02 $0.02 $0.02
    05 Jun 2024 $0.02 $0.00 0.00% 3,628,735 $0.02 $0.02 $0.02
    04 Jun 2024 $0.02 $0.00 0.00% 3,721,870 $0.02 $0.02 $0.02
    03 Jun 2024 $0.02 $0.00 0.00% 1,556,358 $0.02 $0.02 $0.02
    31 May 2024 $0.02 $0.00 0.00% 2,700,412 $0.02 $0.02 $0.02
    30 May 2024 $0.02 $0.00 0.00% 5,657,759 $0.02 $0.02 $0.02
    29 May 2024 $0.02 $0.00 0.00% 3,933,983 $0.02 $0.02 $0.02
    28 May 2024 $0.02 $0.00 0.00% 819,578 $0.02 $0.02 $0.02
    27 May 2024 $0.02 $0.00 0.00% 2,205,465 $0.02 $0.02 $0.02
    24 May 2024 $0.02 $0.00 0.00% 2,370,110 $0.02 $0.02 $0.02
    23 May 2024 $0.02 $0.00 0.00% 5,117,891 $0.02 $0.02 $0.02
    22 May 2024 $0.02 $0.00 0.00% 1,721,921 $0.02 $0.02 $0.02
    21 May 2024 $0.02 $0.00 0.00% 674,994 $0.02 $0.02 $0.02

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    14 Dec 2023 Jennifer Chow Issued 8,643,603 $302,526
    Issue of securities.
    14 Dec 2023 Jennifer Chow Issued 4,062,997 $109,700
    Issue of securities. 4,062,997 Rights
    14 Dec 2023 Jennifer Chow Issued 15,139,467 $408,765
    Issue of options. As per announcement on 15-12-2023
    14 Dec 2023 Eric Sullivan Issued 2,750,000 $74,250
    Issue of options.
    07 Dec 2023 Phillip Hains Issued 3,571,429 $100,000
    Rights issue.
    12 Jul 2023 Leslie (Mi Ok) Chong Issued 108,695 $4,999
    Placement.
    12 Jul 2023 Jennifer Chow Issued 108,695 $4,999
    Placement.
    12 Jul 2023 George Matcham Issued 1,086,956 $49,999
    Placement.
    12 Jul 2023 Cynthia Elkins Issued 108,695 $4,999
    Placement.
    12 Jul 2023 Lesley Russell Issued 1,739,130 $79,999
    Placement.
    12 Jul 2023 Paul Hopper Issued 13,043,478 $599,999
    Placement. As per announcement on 17-07-2023
    23 Jun 2023 Paul Hopper Buy 857,142 $29,999
    Participation in share purchase plan.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Phillip Hains Chief Financial OfficerJoint Company SecretaryNon Executive Director Jul 2023
    Mr Hains has over 30 years of experience in corporate secretarial, accounting and general management through his firm The CFO Solution, a boutique professional services firm for listed companies. Mr Hains is currently the Company Secretary of several ASX listed companies including Imugene Ltd (ASX:IMU), Immuron Ltd (ASX:IMC), SelfWealth Limited (ASX:SWF), Total Brain Limited (ASX:TTB) and SUDA Pharmaceuticals Ltd (ASX:SUD).
    Mr Paul Alex Hopper FounderExecutive ChairmanExecutive Director Feb 2020
    Mr Hopper has over 20 years' experience in the management and funding of biotechnology and healthcare public companies as chairman, chief executive officer and director in Australia and the United States. Mr Hopper's sector experience has covered a number of therapeutic areas with a particular emphasis on immunotherapy. He also has extensive capital markets experience in equity and debt raisings in Australia, Asia, Europe, and the United States.
    Dr Lesley Russell Non-Executive Director Aug 2020
    Dr Russell has over 25 years' experience and leadership in the international pharmaceutical field as a chief medical officer. She has undertaken clinical development in a number of therapeutic areas including haematology/oncology has had multiple new drug approvals with both FDA and European Medicines Agency (EMA). Dr Russell has extensive experience as a director of NASDAQ listed pharmaceutical companies. She is a member of the Royal College of Physicians UK. She is member of the risk committee.
    Mr Eric Sullivan Non-Executive Director Aug 2023
    Mr Sullivan is a senior finance and operations leader in private-to-public biotechnology company building, strategy, fundraising and financial planning. He brings with him an background in the biotechnology sector, having served in senior finance and operations leadership roles across a number of high-growth public biotech companies, including bluebird bio, Merrimack Pharmaceuticals and TCR2 Therapeutics. Additionally, his experience with blue-chip private companies, such as Oncorus, Gemini Therapeutics, and Triplet Therapeutics.
    Mr Nathan Jong Joint Company Secretary
    -
    Eliot Bourk Chief Business Officer
    -
    Jason Litten Chief Medical Officer
    -
    Nathan Jong Joint Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Paul Hopper 94,994,574 17.94%
    Lind Global Fund II LP 17,624,724 3.33%
    Christine Brown 11,696,565 2.21%
    Michael E Barish 11,522,634 2.18%
    Zerrin Investments Pty Ltd 9,600,001 1.81%
    Jennifer Chow 9,450,924 1.79%
    Hsbc Custody Nominees (Australia) Limited 9,437,237 1.78%
    Citicorp Nominees Pty Limited 8,540,926 1.61%
    Shared Office Services Pty Ltd <Philanne S/F A/C> 6,521,739 1.23%
    Valentino Trading Pty Ltd 5,500,000 1.04%
    Kamala Holdings Pty Ltd <The Kamala 1994 S/F A/C> 5,447,142 1.03%
    Australian Direct Investments Pty Limited <Super Fund A/C> 5,060,000 0.96%
    Liberty National Pty Ltd <Liberty National Family A/C> 5,000,000 0.94%
    Ubs Nominees Pty Ltd 4,945,588 0.93%
    Mr Lutz Steffens & Mrs Katy Steffens 4,303,341 0.81%
    Solium Nominees (Australia) Pty Ltd 4,087,272 0.77%
    Mr Tim Bensley & Ms Jenny Jiaer Zhang 3,961,562 0.75%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 3,655,335 0.69%
    Alpha Beta Superannuation Services Pty Ltd <The Alpha Beta Sf A/C> 3,357,142 0.63%
    Brispot Nominees Pty Ltd <House Head Nominee A/C> 3,243,205 0.61%

    Profile

    since

    Note